Chronic treatment with angiotensin AT₁ receptor antagonists reduced serum but not bone TGF-β₁ levels in ovariectomized rats

Author： Li Yong-Qi Ji Hui Shen Yang Ding Li-Ju Zhuang Pei Yang Yu-Lin Huang Qiu-Ju

Publisher： NRC Research Press

ISSN： 1205-7541

Source： Canadian Journal of Physiology and Pharmacology, Vol.87, Iss.1, 2009-01, pp. : 51-55

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Angiotensin II Type 1 receptor antagonists in chronic heart failure

By Collette D Thürmann Petra A

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 5, 2002-05 ,pp. : 705-716

Informa Healthcare

Access to resources Recommend Favorite

Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension

By Smith David H.G.

Drugs, Vol. 68, Iss. 9, 2008-01 ,pp. : 1207-1225

Adis International

Access to resources Recommend Favorite

TGF-β inhibitors for the treatment of cancer

By Lahn Michael Kloeker Susanne Berry Brandi S

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 629-641

Informa Healthcare

Access to resources Recommend Favorite

Functional evidence for the ability of angiotensin AT 1 receptor antagonists to cross the blood-brain barrier in rats

By Polidori C. Ciccocioppo R. Pompei P. Cirillo R. Massi M.

European Journal of Pharmacology, Vol. 307, Iss. 3, 1996-07 ,pp. : 259-267

Elsevier

Access to resources Recommend Favorite

TGF-&bgr; Pathway as a Therapeutic Target in Bone Metastases

Current Pharmaceutical Design, Vol. 16, Iss. 11, 2010-04 ,pp. : 1301-1312

Bentham Science Publishers

Access to resources Recommend Favorite